Prestige Consumer Healthcare (PBH) to Release Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is expected to issue its Q4 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $1.30 per share and revenue of $289.36 million for the quarter. Prestige Consumer Healthcare has set its FY 2025 guidance at 4.500-4.500 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $82.97 on Tuesday. The firm has a market cap of $4.11 billion, a PE ratio of 19.43, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $90.04. The company’s 50-day moving average price is $83.21 and its two-hundred day moving average price is $81.11.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PBH. Oppenheimer raised their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Royal Bank of Canada upped their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a report on Friday, March 21st. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday, April 29th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Canaccord Genuity Group upped their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Insider Buying and Selling

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.